Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04525885
Registration number
NCT04525885
Ethics application status
Date submitted
18/08/2020
Date registered
25/08/2020
Date last updated
27/10/2023
Titles & IDs
Public title
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
Query!
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)
Query!
Secondary ID [1]
0
0
MK-7264-030
Query!
Secondary ID [2]
0
0
7264-030 China Extension
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Gefapixant 45 mg twice daily (BID)
Treatment: Drugs - Gefapixant 15 mg BID
Treatment: Drugs - Placebo
Treatment: Drugs - Gefapixant 45 mg BID
Experimental: Gefapixant 45 mg BID - Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
Experimental: Gefapixant 15 mg BID - Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
Placebo Comparator: Placebo - Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
Treatment: Drugs: Gefapixant 45 mg twice daily (BID)
Gefapixant 45 mg tablet to be administered orally BID
Treatment: Drugs: Gefapixant 15 mg BID
Gefapixant 15 mg tablet to be administered orally BID
Treatment: Drugs: Placebo
Placebo tablet administered orally BID
Treatment: Drugs: Gefapixant 45 mg BID
Gefapixant 45 mg tablet to be administered orally BID
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24
Query!
Assessment method [1]
0
0
24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A longitudinal analysis of covariance (ANCOVA) model was applied to log-transformed cough data to determine geometric mean (GM) 24-hour coughs per hour at baseline and week 24. The GMR (Week 24 GM 24-hour coughs per hour divided by Baseline GM 24-hour coughs per hour) is reported.
Query!
Timepoint [1]
0
0
Baseline, Week 24
Query!
Primary outcome [2]
0
0
Percentage of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up
Query!
Assessment method [2]
0
0
Assessment of participants who have at least one AE during the main study period (24 weeks), the treatment extension period (28 weeks), and during 2 weeks of follow-up by telephone.
Query!
Timepoint [2]
0
0
Up to 54 weeks
Query!
Primary outcome [3]
0
0
Percentage of Participants Who Discontinued Treatment Due to an AE
Query!
Assessment method [3]
0
0
Assessment of participants who stop study treatment due to an AE during the main study period (24 weeks) or the treatment extension period (28 weeks).
Query!
Timepoint [3]
0
0
Up 52 weeks
Query!
Secondary outcome [1]
0
0
Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline
Query!
Assessment method [1]
0
0
Awake coughs per hour was defined as the average hourly cough frequency while the participant is awake, based on a 24-hour interval of sound recordings using a digital recording device (cough monitor). ANCOVA model was applied to log-transformed cough data to determine GM of awake coughs per hour at baseline and week 24. The GMR (Week 24 GM awake coughs per hour divided by Baseline GM awake coughs per hour) is reported.
Query!
Timepoint [1]
0
0
Baseline, Week 24
Query!
Secondary outcome [2]
0
0
Percentage of Participants With a =1.3-point Increase From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24
Query!
Assessment method [2]
0
0
The 19-item LCQ assessed the impact of chronic cough in three health-related quality of life (HRQoL) domains (physical, social and psychological). The LCQ is calculated as a mean score for each domain ranging from 1 to 7, with a total score ranging from 3 to 21. Higher scores indicate better HRQoL. A clinically meaningful improvement from baseline in HRQoL was defined as =1.3-point increase in the LCQ total score at Week 24. The percentage of participants (logistic regression model-based) with a =1.3-point increase in the LCQ total score at Week 24 is presented.
Query!
Timepoint [2]
0
0
Baseline, Week 24
Query!
Secondary outcome [3]
0
0
Percentage of Participants With a =30% Reduction From Baseline in 24-hour Coughs Per Hour at Week 24
Query!
Assessment method [3]
0
0
24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A clinically meaningful improvement from baseline is defined as a =30% reduction in 24-hour coughs per hour at week 24. The percentage of participants (logistic regression model-based) with a =30% reduction from baseline in 24-hour coughs per hour at Week 24 (=30% reduction from baseline) is presented.
Query!
Timepoint [3]
0
0
Baseline, Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Participants With =1.3-point Reduction From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24
Query!
Assessment method [4]
0
0
The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a =1.3 point reduction from baseline in CSD at Week 24 is reported.
Query!
Timepoint [4]
0
0
Baseline, Week 24
Query!
Secondary outcome [5]
0
0
Percentage of Participants With =2.7-point Reduction From Baseline of Mean Weekly CSD Total Score at Week 24
Query!
Assessment method [5]
0
0
The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a =2.7 point reduction from baseline in CSD at Week 24 is reported.
Query!
Timepoint [5]
0
0
Baseline, Week 24
Query!
Secondary outcome [6]
0
0
Percentage of Participants With a =30 mm Reduction From Baseline in Cough Severity Visual Analog Scale (VAS) Score at Week 24
Query!
Assessment method [6]
0
0
The VAS is a single-item questionnaire with the response on a 100- point scale ranging from 0 ("No Cough") to 100 ("Extremely Severe Cough"). Mean weekly VAS score was defined as the average of the VAS scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a =30mm reduction from baseline in cough severity VAS score at Week 24 is reported.
Query!
Timepoint [6]
0
0
Baseline, Week 24
Query!
Eligibility
Key inclusion criteria
- Chest radiograph or computed tomography scan of the thorax (within 5 years of
Screening/Visit 1 and after the onset of chronic cough) not demonstrating any
abnormality considered to be significantly contributing to the chronic cough or any
other clinically significant lung disease in the opinion of the principal investigator
or the sub-investigator
- Has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough
or unexplained chronic cough
- Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or
agrees to follow contraceptive guidance
- Provides written informed consent and is willing and able to comply with the study
protocol (including use of the digital cough recording device and completion of study
questionnaires)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Is a current smoker or has given up smoking within 12 months of Screening, or is a
former smoker with greater than 20 pack-years
- Has a history of respiratory tract infection or recent clinically significant change
in pulmonary status
- Has a history of chronic bronchitis
- Is currently taking an angiotensin converting enzyme inhibitor (ACEI), or has used an
ACEI within 3 months of Screening
- Has an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 at Screening OR
an eGFR =30 mL/min/1.73 m^2 and <50 mL/min/1.73 m^2 at Screening with unstable renal
function
- Has a history of malignancy <=5 years
- Is a user of recreational or illicit drugs or has had a recent history of drug or
alcohol abuse or dependence
- Has a history of anaphylaxis or cutaneous adverse drug reaction (with or without
systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs
- Has a known allergy/sensitivity or contraindication to gefapixant
- Has donated or lost >=1 unit of blood within 8 weeks prior to the first dose of
gefapixant
- Has previously received gefapixant or is currently participating in or has
participated in an interventional clinical study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/05/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
15/09/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
161
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
China
Query!
State/province [1]
0
0
Fujian
Query!
Country [2]
0
0
China
Query!
State/province [2]
0
0
Guangdong
Query!
Country [3]
0
0
China
Query!
State/province [3]
0
0
Inner Mongolia
Query!
Country [4]
0
0
China
Query!
State/province [4]
0
0
Jiangxi
Query!
Country [5]
0
0
China
Query!
State/province [5]
0
0
Liaoning
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Shanghai
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Zhejiang
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Beijing
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04525885
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/ct2/show/NCT04525885
Download to PDF